Effect of Degarelix Administration on Bone Health in Prostate Cancer Patients Without Bone Metastases. The Blade Study.
Carlotta PalumboAlberto Dalla VoltaStefania ZamboniGherardo MazziottiManuel ZampariniLuca TriggianiPaolo BorghettiFilippo MaffezzoniRoberto BrescianiLuca RinaudoFrancesca ValcamonicoDavide FarinaStefano Maria MagriniAlessandro AntonelliClaudio SimeoneAlfredo BerrutiPublished in: The Journal of clinical endocrinology and metabolism (2022)
Degarelix administration is associated with a significant decrease in BMD and increase in bone turnover markers. ALMI is a promising predictor of bone loss in prostate cancer patients receiving androgen deprivation therapy, and ALMI changes during therapy are associated with bone turnover derangement favoring bone quality alterations.